Fosfuro

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fosfuro

Quick Facts

Property Description
Active ingredient Fosfomycin
Form Granules for Oral Solution, Powder for Intravenous Solution
Pharmacological class Systemic Antibacterial Agent, Cell Wall Synthesis Inhibitor
General purpose Elimination of bacteria in infection
Origin Synthetic, Phosphonic Acid Derivative

The Identity of Fosfuro: What Type of Systemic Antibiotic is It?

Fosfuro is a prescription-only medicine whose active component is the substance Fosfomycin, classified as a systemic antibacterial agent. The substance is a phosphonic acid derivative of synthetic origin, belonging to the unique phosphonoacetate class. This compound belongs to its own distinct chemical grouping, separate from penicillins or cephalosporins. This differentiation in chemical structure aligns with its unique mode of antimicrobial action.

Composition and Forms: Oral Trometamol vs. Intravenous Powder

Fosfomycin is offered in several distinct pharmaceutical preparations to allow for different routes of administration. For oral intake, the compound is typically supplied as Fosfomycin trometamol, a specific salt designed to optimize absorption in the digestive tract. This form is most commonly provided as granules for oral solution in a sachet. Fosfomycin is a bactericidal agent that works by inhibiting cell wall synthesis. For use requiring rapid systemic delivery, the medicine is available as a sterile powder for intravenous solution. Fosfomycin is strictly a single-active ingredient product.

General Purpose: Why Fosfomycin is a Broad-Spectrum Bactericidal Agent

The overall general purpose of Fosfomycin is to effectively and directly eliminate bacteria that cause infection, qualifying it as a broad-spectrum antibiotic with bactericidal properties. The drug's activity covers infections caused by both Gram-positive and Gram-negative bacteria, offering a distinct advantage. Its unique mechanism involves an irreversible targeted blockade of building blocks essential for the formation of the bacterial cell wall. This specific, early-stage interference helps ensure the drug maintains a wide scope of activity, giving it the capacity to address a variety of microbial threats.

What side effects are possible with Fosfuro?

Possible side effects and safety information

The safety profile of Fosfomycin (Fosfuro) is structured in official regulatory documents by the frequency and type of adverse reactions observed during clinical use. These effects are grouped according to the body system affected, a classification system known as System-Organ Classes.

Adverse Reaction Frequencies

Side effects are officially classified by likelihood. Common reactions reported for both the oral and intravenous forms typically include gastrointestinal issues such as diarrhoea, nausea, and vomiting, as well as headache. For the oral formulation, vaginitis is also classified as common. The intravenous form often involves a very common reaction of pain at the injection site. Uncommon reactions may include dizziness, rash, pruritus, and minor, reversible changes in blood values like elevated transaminases or eosinophilia.

Serious Adverse Reactions and Safety Constraints

Official labeling documents certain serious adverse reactions, where the frequency is generally classified as not known due to their rarity. These include severe hypersensitivity reactions such as anaphylactic shock and angioedema. Furthermore, the development of Clostridium difficile-associated diarrhoea (CDAD), a serious bowel condition, is noted as a risk that may occur during or even after treatment completion.

Specific safety considerations are mandated for certain patient groups. The intravenous formulation requires dose adjustments in individuals with renal impairment to prevent drug accumulation and related adverse events. This formulation also carries a caution regarding its high sodium load, which acts as a safety limitation for specific patients, such as those with severe electrolyte imbalance.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Phosphine/Metallic Phosphides

Overdose scope

  • Documented overdose presentations: Initial, non-specific symptoms include headache, dizziness, fatigue, nausea, vomiting, and loss of appetite. Severe manifestations include labored breathing, pulmonary edema (fluid in the lungs), chest tightness, and profound hypotension (low blood pressure), often leading to cardiovascular collapse.
  • Physiological systems affected (as stated in label): The substance is a multisystem toxicant affecting the cardiovascular, respiratory, central nervous, hepatic (liver), and renal (kidney) systems.
  • Dose-related or exposure-related factors (if applicable): Toxicity arises primarily from the release of highly toxic Phosphine gas when metal phosphides react with water or moisture. The odor is not a reliable warning sign of hazardous concentrations. Exposure can occur via inhalation of the gas or ingestion of the solid phosphide (e.g., in pesticides).
  • Population-specific overdose notes (if applicable): No specific population-based risk factors are universally defined, as the toxicity is considered severe for all exposed individuals.

Emergency-response statements (as written in official documents):

  • No antidote for phosphine poisoning is available; treatment focuses strictly on the support of critical respiratory and cardiovascular functions.
  • Secondary contamination risk exists from solid phosphides on skin or clothes, which continue to release toxic gas.
  • When immediate medical help is required (label-derived phrasing only): Medical help must be sought immediately if overexposure is suspected or if any symptoms develop, as the substance is classified as Immediately Dangerous to Life or Health (IDLH). Severe, life-threatening damage, such as liver failure, may be delayed by several days.

Resulting overdose structure

  • Official overdose statements: The most serious outcomes are cardiovascular collapse, which may occur within the first 24 hours, and delayed death due to liver or kidney failure. Given the lack of an antidote, official guidance mandates prompt medical consultation regardless of the presence or absence of initial symptoms.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile of metallic phosphides as an acute, severe poisoning risk where intervention must be sought immediately due to the chemical's IDLH classification and the risk of rapid, fatal cardiovascular injury. The required emergency action centers on life-supportive care, as no substance is authorized as a specific neutralizing agent for the toxicity.

Therapeutic Uses of Fosfuro

What Fosfomycin Treats: Main Uses and Benefits

Fosfomycin is applied across distinct clinical domains, with the goal of supporting relief from pronounced and disruptive symptoms. The medication is considered relevant for managing different severities of bacterial infection, from acute, lower-tract conditions to severe, systemic manifestations.


Therapeutic Applications and Symptom Support

This medication is commonly used for conditions presenting with acute, localized discomfort, primarily uncomplicated cystitis in adult women, and is relevant for more complex scenarios, including complicated urinary tract infections, prostatitis, and prophylaxis following transurethral surgery. It is also applied in situations involving heightened systemic burden, such as managing serious bone and joint infections or bacteremia.

It helps address symptom clusters that interfere with daily functioning, such as acute discomfort (painful urination, urinary urgency) and systemic markers (fever, localized inflammatory pain). The medication contributes to improved day-to-day comfort by helping to ease these disruptive manifestations.

“Fosfomycin is relevant in situations where short-term symptomatic assistance is needed to address infection and maintain functional stability.”


Symptom Support Summary

Property Description
Primary Symptom Focus Acute Dysuria and Urinary Urgency
Core Therapeutic Benefit Contributes to easing the overall symptom load
Typical Scenario Outpatient treatment of uncomplicated bladder infection
Severity Relevance Acute, episodic, and recurrent manifestations

Regulatory References

  1. European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Fosfuro, which contains the active ingredient fosfomycin, is primarily prescribed for the treatment of acute, uncomplicated urinary tract infections (UTIs) caused by susceptible bacteria. The oral granular form is typically indicated for adult women and female adolescents aged 12 years and older.

Usage of this antibiotic is generally restricted in certain populations or conditions due to safety concerns or reduced efficacy. You should not take Fosfuro if any of the following apply:

  • Known allergy or hypersensitivity to fosfomycin or any other ingredient in the formulation.
  • Severe renal impairment, specifically with a creatinine clearance below 10 mL/ min or if you are undergoing hemodialysis.
  • Children under 12 years of age.

Special Considerations

Patient Group Recommendation
Pregnancy Use should be considered only if clearly necessary and potential benefit outweighs the risk, under a doctor’s guidance.
Breastfeeding Fosfomycin is excreted into breast milk; use must be carefully considered by a healthcare professional.

Additionally, be sure to inform your healthcare provider about all current medications, especially metoclopramide or other drugs that increase gut motility, as these can lower the effectiveness of Fosfuro.

What should I know about interactions with other medicines?

Fosfuro (fosfomycin) can interact with a variety of other medications and substances, potentially altering its effectiveness or increasing the risk of side effects. It is important to inform your healthcare provider about all prescription and over-the-counter medicines, vitamins, herbal supplements, and other products you are currently using.


Drug-Drug Interactions

Fosfomycin's absorption and efficacy can be significantly reduced by drugs that increase gastrointestinal motility. The most notable example is metoclopramide, which should generally be avoided or taken with appropriate spacing from Fosfuro. Additionally, some serious interactions exist with live bacterial vaccines, such as the oral typhoid vaccine and cholera vaccine, which may be inactivated by the antibiotic effect of Fosfuro. Concurrent use with these vaccines is not recommended.


Food and Other Interactions

Food

Taking Fosfuro with food may lead to a decrease in its absorption, potentially lowering its concentration in the urine and reducing its effectiveness against a urinary tract infection. Therefore, it is typically advised to take Fosfuro on an empty stomach (at least one hour before or two hours after a meal) to optimize its therapeutic effect.

Other Products

No clinically significant interactions are consistently reported with alcohol or tobacco use, but general caution is always advised when combining any medication with these substances.

Mechanism of Action

Infiltration and Irreversible Enzyme Blockade

The cellular action of Fosfomycin begins with its active molecular infiltration, where it is actively transported into the bacterial cytoplasm using the microbes' own nutrient uptake systems: the GlpT and UhpT transporters. Once inside, Fosfomycin acts as a structural mimic of phosphoenolpyruvate (PEP) and irreversibly inhibits the essential enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). The drug achieves this by binding covalently to a cysteine residue in the enzyme's active site, causing its permanent deactivation. This action stops the first committed step in the bacteria's peptidoglycan synthesis pathway.

Structural Collapse and Bactericidal Effect

The MurA blockade prevents the synthesis of crucial cell wall precursors. Without these building blocks, the bacteria cannot construct or maintain a structurally sound cell wall, which is necessary to resist high internal osmotic pressure. This loss of structural integrity causes the bacterial cell to rapidly rupture and disintegrate (lysis), resulting in a direct bactericidal physiological effect. Resistance to this process can occur if the bacteria mutate the GlpT/UhpT transporters or acquire enzymes that chemically inactivate the Fosfomycin molecule, leading to a reduction or absence of bactericidal activity.

Dosage and Administration Information

How Fosfuro is Used: Official Administration and Dosing Principles

Fosfuro (Fosfomycin) is prescribed for use via two distinct routes, which determine the form of the medicine and the duration of treatment. The approved routes are Oral (as granules for solution) and Intravenous (IV) (as a powder for solution).


Standard Labeled Dosing and Scheduling

Administration Route Typical Adult Dosing Regimen Frequency & Duration Key Administration Note
Oral (3 g Sachet) A single, one-time dose of 3 g. Once-only (one day) for uncomplicated acute cystitis. Must be dissolved in 3-4 ounces of cool water; consumed immediately.
Intravenous (IV) 12-24 g daily in 2-4 divided doses or 6 g every 8 hours. Multi-dose schedule; treatment may last up to 14 days. Administered as an infusion over a minimum time, often ge 30 minutes.

Administration Conditions and Adjustments

Official instructions provide specific guidance regarding the conditions of use:

  • Oral Intake: The granules must be fully dissolved in cool water and are strictly not to be taken in their dry form or with hot liquids. Intake may occur with or without food, or may be directed to be taken on an empty stomach.
  • Renal Function: The total daily IV dose requires mandated reduction in patients with renal impairment (e.g., creatinine clearance less than 40 mL/min). The initial dose, or loading dose, is typically administered before the reduction takes effect. This ensures the medicine is used in accordance with established pharmacokinetic principles.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fosfuro

This overview summarizes the research structure and the evidence base for Fosfuro (Fosfomycin), focusing on how the medicine has been evaluated in official clinical settings. The purpose here is to describe the studies that exist, what they measured, and what remains uncertain, without providing any medical or usage advice.


Research Evidence for Acute Uncomplicated Cystitis (Bladder Infection)

Fosfomycin was studied in numerous short-term randomized controlled trials (RCTs) across conditions characterized by fluctuating or episodic manifestations, such as acute, uncomplicated bladder infections. These trials included treatments used as comparators in the same condition. Researchers monitored specific outcomes related to physical discomfort, such as the resolution of painful or urgent urination, and microbiological eradication, which is the clearance of the causative bacteria from the patient's urine. Studies report how symptoms evolved in the observed populations, with many trials describing patterns of favorable measurements of symptom resolution and bacterial clearance in the short-term. Comparisons described patterns where the measured outcomes were measured within a range consistent with other treatments in the intermediate follow-up periods.


Studies for Complicated Urinary Tract Infections (cUTI)

For more complex urinary tract infections (cUTI), the evidence base differs significantly. Research was conducted primarily through retrospective analyses and observational studies, rather than dedicated, large-scale RCTs. Studies examined patients with functional limitations or underlying structural issues, often focusing on infections caused by multi-drug-resistant (MDR) bacteria. Research describes patterns observed in these studies, where patients receiving Fosfomycin, usually in combination with another antibiotic, often reported measurements of clinical success in complex cases. Because the drug was usually studied in combination with other antibiotics, the independent contribution of Fosfomycin alone to the final outcome is difficult to isolate from existing data.


Research Gaps and Areas of Uncertainty

Despite the research on Fosfomycin, particularly for acute bladder infections, several research gaps and uncertainties remain. The long-term effects are not fully established, as follow-up durations were limited to the short-to-intermediate term in many trials. For serious systemic conditions, the evidence quality varies across studies, with a lack of dedicated, modern, and large-scale Randomized Controlled Trials (RCTs) using Fosfomycin as a single agent. Data for certain special groups, outside of the main adult female population for uncomplicated cystitis, remain insufficient to inform broad conclusions.

Key Studies & References

  1. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials
  2. Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies

Frequently Asked Questions (FAQ)

Common questions about Fosfuro (FAQ)

Q: How quickly does Fosfuro start working after taking it?

A: Official information indicates that after taking the oral dose, the active component of Fosfuro typically reaches its highest concentration in the blood within about two hours. The drug is primarily eliminated in the urine over about three days, which provides an estimate of its presence in the urinary tract.

Q: How long do I need to take Fosfuro for a standard infection?

A: According to regulatory documents, for a standard, uncomplicated bladder infection in women, the oral form of Fosfuro is typically administered as a single, one-time dose. For more complex infections, or when using the intravenous form, a multi-dose treatment schedule may be necessary, and this duration can extend up to 14 days.

Q: What happens if I miss a dose of Fosfuro?

A: Since the oral treatment is given as a single dose, instructions for a missed dose do not typically apply. For the multi-dose intravenous treatment, if the next scheduled dose is less than two hours away, official guidelines indicate skipping the missed dose and resuming the regular schedule.

Q: Can people with kidney problems use Fosfuro?

A: The medicine is generally not suitable for individuals with severe kidney impairment, specifically those with a creatinine clearance below 10 mL/min or those receiving hemodialysis. Furthermore, the intravenous form requires a mandated dose reduction for patients with any degree of renal impairment to prevent the drug from accumulating in the system.

Q: Is it normal to feel a bit nauseous after taking Fosfuro?

A: Yes, regulatory documents classify nausea as a common gastrointestinal side effect for both the oral and intravenous forms of Fosfuro. This means that a significant number of people taking the medicine may experience some nausea or stomach upset.

Q: Can men use Fosfuro for the conditions it treats?

A: The oral formulation is primarily indicated for acute, uncomplicated bladder infections in women and female adolescents. Some regulatory bodies, however, have also authorized its use in men for certain procedures, such as preventing infection associated with transrectal prostate biopsy.

Q: Do many people experience stomach upset with Fosfuro?

A: Official product information classifies common gastrointestinal problems, including diarrhoea, nausea, and vomiting, as 'common adverse reactions.' This classification indicates that these effects are frequently reported by patients taking the medicine.

Q: Can I drive or operate machinery while taking Fosfuro?

A: Because dizziness is listed as an uncommon side effect of Fosfuro, the product information advises caution regarding activities that require alertness, such as driving or operating machinery. Patients are advised to note how the medicine affects them before engaging in such activities.

Q: How long after finishing Fosfuro should I expect to feel completely better?

A: Clinical studies and official information suggest that an improvement or full resolution of symptoms typically occurs within two to three days after the single oral dose is taken. However, individual recovery times can vary.

Q: Does Fosfuro affect alcohol consumption?

A: According to authoritative sources, no clinically significant interactions are consistently reported between Fosfuro and alcohol or tobacco use. Nevertheless, general caution is always advised when combining any medication with these substances.

Q: Does Fosfuro affect blood sugar levels?

A: Regulatory documents do not commonly list specific effects on blood sugar (glucose) levels as a known or expected side effect. In clinical trials, any changes to serum chemistry were generally found to be minor and temporary.

Q: Can people with liver issues safely take Fosfuro?

A: The body primarily eliminates Fosfomycin through the kidneys, and the drug is primarily processed and eliminated by the kidneys. While monitoring is generally recommended for those with underlying liver disease, significant liver-related adverse events are not commonly reported in the product labeling.

Q: What happens if I accidentally take too much Fosfuro?

A: If too much Fosfuro is taken, symptoms of an overdose may include excessive drowsiness, muscle weakness, and electrolyte imbalance. In the event of a suspected overdose, official guidance is to seek immediate medical attention or contact a Poison Control Centre.

Q: How long does Fosfuro stays in your system after the last dose?

A: The mean elimination half-life of Fosfomycin is documented to be approximately 5.7 hours. This means it takes about that amount of time for the body to clear half of the drug. The medicine is effectively eliminated from the body within a few days of the last dose.

How should Fosfuro be stored and disposed of?

How to Store and Dispose of Fosfomycin

Fosfomycin storage and disposal are governed by official regulatory requirements to maintain product stability and safety.

Storage Conditions

Unopened Product: The oral granules must be stored at room temperature (e.g., 20 C to 25 C), away from excess heat and moisture. The intravenous powder requires storage below 25 C and protected from light.

Prepared Solution: The oral solution must be consumed immediately after mixing. The prepared IV solution is stable for up to 24 hours when kept refrigerated (2 C to 8 C). The medication must always be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Fosfomycin should not be disposed of via wastewater or household waste. Disposal must be performed in accordance with local requirements by consulting a pharmacist, ensuring environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fosfuro found in:

A-Z Index: